The semaglutide impurity endo-20a-Glu-SMT is a structural analogue of semaglutide (a long-acting glucose-lowering drug based on GLP-1, used to treat type 2 diabetes and obesity) that may be produced during the synthesis or storage process. This impurity is formed by the modification of glutamic acid (Glu), and its presence may affect the chemical purity, stability and biological activity of the drug. During the drug development and production process, it is necessary to monitor and control the level of such impurities through strict quality control methods (such as HPLC, mass spectrometry, etc.) to ensure that the safety and therapeutic efficacy of the final drug meet the international pharmacopoeia standards.
Product Overview
Basic Description |
Structure and function: |
Three-letter sequence |
H-His-Ala-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Lys-Glu-Ile-Trp-Leu-Val-Lys-Gly-Asp-Val-Arg-Arg-Arg-Arg-Arg-Arg-Gly-CONH2 |
Single letter sequence |
HHAEGTFTSDVSSYLEGQAKEITWLVLVKGDVRRAARRRRG-NH2 |
Molecular formula |
C187H290N54O59S |
Molecular weight |
4106.14 g/mol |
Product Attributes
purity |
>98% |
form |
Lyophilized powder |
Storage conditions |
Store at -20°C/-80°C away from light |